Author: Kumaki, Yohichi; Ennis, Jane; Rahbar, Ramtin; Turner, Jeffrey D.; Wandersee, Miles K.; Smith, Aaron J.; Bailey, Kevin W.; Vest, Zachary G.; Madsen, Jason R.; Li, Joseph K.-K.; Barnard, Dale L.
                    Title: Single-dose intranasal administration with mDEF201 (adenovirus vectored mouse interferon-alpha) confers protection from mortality in a lethal SARS-CoV BALB/c mouse model  Cord-id: q9tstj31  Document date: 2011_1_1
                    ID: q9tstj31
                    
                    Snippet: Interferons (IFNs) are a first line of defense against viral infection. Herein we describe the use of an adenovirus vectored mouse IFN alpha gene (mDEF201) as a prophylactic and treatment countermeasure in a SARS-CoV-infected BALB/c mouse model. Complete survival protection was observed in mice given a single dose of mDEF201 administered intranasally 1, 3, 5, 7, or 14 days prior to lethal SARS-CoV challenge (p<0.001), and body weights of these treated mice were unaffected by the challenge. In ad
                    
                    
                    
                     
                    
                    
                    
                    
                        
                            
                                Document: Interferons (IFNs) are a first line of defense against viral infection. Herein we describe the use of an adenovirus vectored mouse IFN alpha gene (mDEF201) as a prophylactic and treatment countermeasure in a SARS-CoV-infected BALB/c mouse model. Complete survival protection was observed in mice given a single dose of mDEF201 administered intranasally 1, 3, 5, 7, or 14 days prior to lethal SARS-CoV challenge (p<0.001), and body weights of these treated mice were unaffected by the challenge. In addition, low doses of mDEF201 protected lungs in a dose dependent manner as measured by a reduction in gross pathology. Intranasal treatment with mDEF201 ranging from 10(6) to 10(8) PFU significantly protected mice against a lethal SARS-CoV infection in a dose dependent manner up to 12 h post infection (P<0.001). The data suggest that mDEF201 is a new class of antiviral agent further development as treatment for SARS-CoV infections.
 
  Search related documents: 
                                Co phrase  search for related documents- acute respiratory syndrome and administration time dose: 1, 2, 3, 4
  - acute respiratory syndrome and live number: 1, 2
  - acute respiratory syndrome and logrank test: 1
  - acute respiratory syndrome and lung pathology: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
  - acute respiratory syndrome and lung sample: 1, 2, 3, 4
  - acute respiratory syndrome and lung score: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59
  - acute respiratory syndrome and lung score difference: 1, 2, 3
  - acute respiratory syndrome and lung surface: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
  - acute respiratory syndrome and lung surface area: 1
  - acute respiratory syndrome and lung titer: 1, 2, 3, 4, 5, 6, 7, 8, 9
  - acute respiratory syndrome and lung virus titer: 1, 2, 3, 4
  - acute respiratory syndrome and lung weight: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38
  - acute respiratory syndrome and lymphatic cell: 1
  - acute respiratory syndrome and macaca fascicularis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
  - acute respiratory syndrome and macaque model: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
  
 
                                Co phrase  search for related documents, hyperlinks ordered by date